QT interval prolongation and ventricular arrhythmias can occur with coadministration. Avoid coadministration of oxaliplatin with medicinal products with known potential to prolong QT interval.
Source: NLP:oxaliplatin
Oxaliplatin Interactions
Brand names: Oxaliplatin
Platinum-based Drug
Route: Intravenous
FDA Black Box Warning
WARNING: HYPERSENSITIVITY REACTIONS, INCLUDING ANAPHYLAXIS Serious and fatal hypersensitivity adverse reactions, including anaphylaxis, can occur with oxaliplatin within minutes of administration and during any cycle. Oxaliplatin is contraindicated in patients with hypersensitivity reactions to oxaliplatin and other platinum-based drugs [see Contraindications (4) ] . Immediately and permanently discontinue oxaliplatin for hypersensitivity reactions and administer appropriate treatment for management of the hypersensitivity reaction [see Warnings and Precautions (5.1) ] . WARNING: HYPERSENSITIVITY REACTIONS, INCLUDING ANAPHYLAXIS See full prescribing information for complete boxed warning. Serious and fatal hypersensitivity adverse reactions, including anaphylaxis, can occur with oxaliplatin injection within minutes of administration and during any cycle. Oxaliplatin injection is contraindicated in patients with hypersensitivity reactions to oxaliplatin and other platinum-based drugs. Immediately and permanently discontinue oxaliplatin injection for hypersensitivity reactions and administer appropriate treatment. ( 4 , 5.1 )
Contraindications
4 CONTRAINDICATIONS Oxaliplatin injection is contraindicated in patients with a history of a hypersensitivity reaction to oxaliplatin or other platinum-based drugs. Reactions have included anaphylaxis [see Warnings and Precautions (5.1) ] . • History of hypersensitivity reaction to oxaliplatin or other platinum-based drugs. ( 4 , 5.1 )
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary Based on its direct interaction with DNA, oxaliplatin can cause fetal harm when administered to a pregnant woman. The available human data do not establish the presence or absence of major birth defects or miscarriage related to the use of oxaliplatin. Reproductive toxicity studies demonstrated adverse effects on embryo-fetal development in rats at maternal doses that were below the recommended human dose based on body surface area ( see Data ). Advise a pregnant woman of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal data Pregnant rats were administered oxaliplatin at less than one-tenth the recommended human dose based on body surface area during gestation days (GD) 1 to 5 (preimplantation), GD 6 to 10, or GD 11 to 16 (during organogenesis). Oxaliplatin caused developmental mortality (increased early resorptions) when administered on days GD 6 to 10 and GD 11 to 16 and adversely affected fetal growth (decreased fetal weight, delayed ossification) when administered on days GD 6 to 10.
9 interactions on record
Prolonged prothrombin time and INR occasionally associated with hemorrhage reported when used with oxaliplatin, especially with oral anticoagulants. Increase monitoring frequency.
Source: NLP:oxaliplatin
Clearance of platinum-containing species may be decreased by coadministration of nephrotoxic compounds due to renal elimination. Avoid coadministration.
Source: NLP:oxaliplatin
QT interval prolongation and ventricular arrhythmias can occur with oxaliplatin. Avoid coadministration.
Source: NLP:oxaliplatin
Platinum-containing species eliminated primarily through kidney; clearance may be decreased by coadministration of potentially nephrotoxic compounds.
Source: NLP:oxaliplatin
Clearance of platinum-containing species may be decreased by coadministration of nephrotoxic compounds. Coadministration should be avoided.
Source: NLP:oxaliplatin
Prolonged prothrombin time and INR occasionally associated with hemorrhage reported in patients receiving oxaliplatin with fluorouracil/leucovorin. Increase monitoring frequency.
Source: NLP:oxaliplatin
QT interval prolongation and ventricular arrhythmias can occur. Avoid coadministration with medicinal products with known potential to prolong QT interval.
Source: NLP:oxaliplatin
Oxaliplatin + LeucovorinModerate
Prolonged prothrombin time and INR occasionally associated with hemorrhage reported when oxaliplatin combined with fluorouracil/leucovorin in patients on anticoagulants. Increase frequency of monitoring.
Source: NLP:oxaliplatin